One of the seeming shortcomings of BETonMACE is the lack of a pitavastatin (aka, Livalo) arm. Some consider pitavastatin potentially superior to other statins due to superior ability in raising apoA-I/HDL levels (by increasing production of lipid-poor AI-HDL, particles that may have high functional capacity with respect to reducing atheroma plaque). Pita has been shown efficacious in marked reduction of coronary atheroma volume in ACS patients (JAPAN-ACS trial). Pita also increases LDL-C target attainment rates with similar or greater efficacy to comparable doses of atorvastatin, simvastatin and pravastatin and may be of added benefit in high-risk patients with elevated TG-rich particles, low and or dysfunctional HDL (the presumptive sweet spot for apabetalone) - as well as patients with considerable persistent residual risk even when LDL-C levels are on-goal. Any potential synergy between pita and apabetalone with respect to boosting functional HDL, reducing vascular inflammation, enhancing plaque regression and reduction of MACE  awaits another long round of outcomes studies. If this proves beneficial, one could only hope for similar perks in CKD and neuroinflammatory conditions like AD.